Fc epsilon RI alpha

Fc epsilon RI alpha

Fc epsilon RI alpha Informations sur la molécule

Molecule Name
IgE Fc receptor, alpha-subunit
Alias de la molécule
FCER1A,FCE1A,FcERI
Drug Development Progress
Nombre de médicaments cliniques1
Nombre de médicaments commercialisés1
Phase de R&D la plus avancéeApproved
Alias de la cible
Fc Fragment Of IgE, High Affinity I, Receptor For; Alpha Polypeptide,FCE1A,IgE Fc receptor subunit alpha,Fc-epsilon RI-alpha,FCER1A,Fc Fragment Of IgE Receptor Ia,Fc Fragment Of IgE, High Affinity I, Receptor For,Alpha Polypeptide,Fc Epsilon Receptor Ia,FcERI,Immunoglobulin E Receptor, High-Affinity, Of Mast Cells, Alpha Polypeptide,High Affinity Immunoglobulin Epsilon Receptor Alpha-Subunit,High Affinity Immunoglobulin Epsilon Receptor Subunit Alpha,Fc IgE Receptor, Alpha Polypeptide,Fc Epsilon RI Alpha-Chain,FCER1
Contexte de la molécule
High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A) is also known as Fc-epsilon RI-alpha (FcERI), IgE Fc receptor subunit alpha, FCE1A. FCER1A contains two Ig-like (immunoglobulin-like) domains. FCER1A binds to the Fc region of immunoglobulins epsilon and is a high affinity receptor. FCER1A is responsible for initiating the allergic response, which binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines. FCER1A plays a central role in allergic disease, coupling allergen and mast cell to initiate the inflammatory and immediate hypersensitivity responses that are characteristic of disorders such as hay fever and asthma.

Fc epsilon RI alpha Liste de produits

Species
  • Human(3)
  • Cynomolgus(2)
  • Mouse(1)
Tag
  • Fc Tag(3)
  • His Tag(2)
  • His Tag & Avi Tag(1)
Host
  • HEK293(6)
Conjugate
  • Unconjugated(5)
  • Biotin-labeled(1)
Grade
  • RUO(6)
Low Endotoxin
  • Yes(1)
  • No(5)
You Have Viewed 1-6 Of 6 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
LesigerceptYH-35324; GI-301Phase 2 ClinicalYuhan Corp
Chronic Urticaria; Hypersensitivity; Immune System Diseases; Urinary Tract Infections; Urticaria
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Benzylpenicilloyl PolylysineApprovedAllerquest LlcPre-penUnited StatesAnaphylaxis; Diagnostic agentsAllerquest Inc1974-07-25
Anaphylaxis; Diagnostic agents
Details
Customer Reviews